Pages

▼
Monday, January 22, 2024

Results From A Phase-IIΔ Baricitinib (Olumiant)

›
Baricitinib (trade name Olumiant) is a drug which targets the immune system, and is already approved for Rheumatoid Arthritis (since 2018) a...
1 comment:
Saturday, January 6, 2024

What To Watch In 2024

›
At the start of a new year, some bloggers write a posting on the year that was, and a some write a posting on what they expect in the new ye...
1 comment:
Sunday, December 24, 2023

Diamyd Update

›
This is my first update on the Diamyd company in many, many years.  It is focused on their DIAGNODE-3 clinical trial, but before I discuss t...
Saturday, December 16, 2023

Islet Cell Transplantation Clinical Trails

›
In this blog I'm going to report on three different clinical trials involving transplantation.  The basic idea for all of these is to tr...
Tuesday, November 28, 2023

Teplizumab/Tzield Reports Results From A Phase-III in Honeymooners (PROTECT)

›
Teplizumab (sold as Tzield) was recently approved for use in people at-risk of diagnosis for T1D.  At risk meaning people who have two auto...
Saturday, November 11, 2023

JDRF Funding for a Cure 2023

›
In the US, we are in the "Walking Season" when JDRF (Juvenile Diabetes Research Foundation) asks us to walk to raise money for a ...
Monday, October 9, 2023

DFMO Starts A Phase-II Clinical Trial (TADPOL)

›
Difluoromethylornithine (DFMO), also known as Eflornithine, is FDA approved since 1990 as an injection to treat African Sleeping Sickness (t...